Compare Eli Lilly And Co (LLY) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Sony Group Corp — how do they compare? Eli Lilly And Co trades at $1,141 (market cap $1.02T), while Sony Group Corp trades at $21.2 (market cap $125.96B). The key difference: Eli Lilly And Co is far larger — about 8.1× Sony Group Corp's market cap, and Sony Group Corp pays the higher dividend (0.75%). Which is the better fit depends on your goals.
| LLY | SONY | |
|---|---|---|
Market Cap | $1.02T | $125.96B |
Sector | Health | Technology |
52-Week High | $1.24K | $30.26 |
52-Week Low | $625.65 | $19.32 |
Enterprise Value | $1.06T | $122.45B |
Dividend Yield | 0.6% | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Sony trades at $21.165 with modest daily gains of 0.21%, supported by strong technical momentum and bullish analyst sentiment. The company demonstrates solid fundamentals with $12.96T in revenue and $1.14T net income for 2025, though recent Q1 2026 earnings missed expectations. Sony's entertainment strategy expansion and digital gaming transition position it for long-term growth despite near-term execution risks.
Sony presents a compelling investment case with strong cash flow generation and analyst support, though investors must monitor the digital gaming transition execution and potential revenue volatility. The stock's current valuation metrics appear reasonable given the company's market position and growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
